According to DelveInsight’s analysis, the market for cystic fibrosis is anticipated to increase during the forecast period (2024–2034), owing to the launch...
LOS GATOS, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC: ARDS) (“Aridis” or the “Company”), a biopharmaceutical company,...
The global Vaccine Adjuvants market size is expected to reach USD 2.90 billion by 2030 and exhibit a CAGR of 11.9% in the forecast period (2023−2030),...
LOS GATOS, Calif., Dec. 15, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC QB: ARDS), a biopharmaceutical company focused on the discovery...
Received two grant awards from the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health LOS GATOS,...
NEW YORK, Sept. 07, 2023 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common stock of Nymox Pharmaceutical Corporation. Nymox Pharmaceutical Corporation's securities were
Gainers Bright Green Corp. (NASDAQ: BGXX) jumped 90.5% to close at $48.08 on Wednesday. Bright Green Corporation, went public on the NASDAQ Tuesday, becoming the first U.S. plant-touching company to list on a major U.S. stock exchange.
The Cystic Fibrosis (CF) therapeutic development pipeline contains candidate drugs that address many different aspects of the disease. Drug development for...